SignaBlok awarded NIAAA / NIH SBIR Phase I grant to test new approach to treatment of alcoholic liver disease
SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new nanotechnology for diagnostic imaging of atherosclerosis